Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1759 clinical trials
featured
A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non Small Cell Lung Cancer

  • 314 views
  • 25 Mar, 2021
  • 4 locations
featured
Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias

Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias

  • 6 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Characterize the safety and tolerability, and evaluate Pharmacokinetics of MRTX849 in combination with TNO155 in patients with advanced solid tumor malignancies with KRAS G12C mutation.

solid tumor
advanced solid tumor
solid tumors
malignant solid tumor
  • 114 views
  • 19 Feb, 2021
  • 10 locations
featured
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that inhibits several closely

systemic therapy
ipilimumab
carcinoma
monoclonal antibodies
nivolumab
  • 27 views
  • 15 Sep, 2020
  • 1 location
featured
EAY131: Molecular Analysis for Therapy Choice (MATCH)

EAY131: Molecular Analysis for Therapy Choice (MATCH)

lymphoma
multiple myeloma
solid tumors
  • 98 views
  • 24 Nov, 2020
  • 1 location
featured
Alliance A071701 Genomically-Guided Treatment Trial in Brain Metastases

People with recurrent or progressive brain metastases may be eligible for this trial.  All tumors will be submitted to the Alliance biorepository for tracking and processing.  Samples will undergo central biomarker testing.  Patient's tumor samples will be tested for the presence of mutations predicting sensitivity to each inhibitor.  Patients harboring …

brain tumors
brain tumor
solid tumors
brain metastases
solid tumor
  • 40 views
  • 24 Jun, 2021
  • 1 location
featured
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma

  • 220 views
  • 25 Mar, 2021
  • 1 location
featured
Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

  • 114 views
  • 08 Nov, 2020
  • 1 location
featured
ANBL00B1: Biomarkers in Tumor Tissue Samples from Patients with Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

ANBL00B1: Biomarkers in Tumor Tissue Samples from Patients with Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  • 104 views
  • 08 Nov, 2020
  • 1 location
AMG 404 in Patients With Advanced Solid Tumors.

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.

  • 87 views
  • 07 Jul, 2021
  • 57 locations